Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AVYCAZ vs ANCEF IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
AVYCAZ is a combination of ceftazidime, a cephalosporin beta-lactam antibiotic, and avibactam, a non-beta-lactam beta-lactamase inhibitor. Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis. Avibactam protects ceftazidime from degradation by certain beta-lactamases, including Ambler class A, class C, and some class D enzymes.
Cefazolin, a first-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking and autolytic enzyme inhibition.
Complicated intra-abdominal infections (c IAI) in combination with metronidazole,Complicated urinary tract infections (c UTI) including pyelonephritis,Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP)
Perioperative prophylaxis,Urinary tract infections,Respiratory tract infections,Skin and soft tissue infections,Biliary tract infections,Bone and joint infections,Septicemia,Endocarditis,Off-label: Intra-amniotic infection (chorioamnionitis)
1 vial (ceftazidime 2g and avibactam 0.5g) IV over 2 hours every 8 hours.
1-2 g IV/IM every 8 hours. Maximum 12 g/day.
Ceftazidime: ~2.8 hours; avibactam: ~2.7 hours. Extended in renal impairment (e.g., Cr Cl <50 m L/min requires dose adjustment).
1.5-2 hours in adults with normal renal function; prolonged to 10-30 hours in ESRD (Cr Cl <10 m L/min); anephric patients up to 40 hours.
Ceftazidime is primarily excreted unchanged by the kidneys via glomerular filtration. Avibactam is also primarily eliminated renally and undergoes minimal metabolism. The metabolism of both components is not significantly mediated by cytochrome P450 enzymes.
Cefazolin undergoes minimal hepatic metabolism; primarily excreted unchanged by the kidneys via glomerular filtration and tubular secretion.
Ceftazidime: primarily renal (80-90% unchanged); avibactam: primarily renal (85-95% unchanged). Fecal excretion <1%.
Primarily renal (80-96% unchanged within 24 hours via glomerular filtration and tubular secretion); minimal biliary (<1%) and fecal (<1%).
Ceftazidime: ~10% bound to albumin; avibactam: ~8% bound to human plasma proteins.
80-86% primarily to albumin.
Ceftazidime: ~0.19 L/kg; avibactam: ~0.29 L/kg. Indicates extensive distribution into extracellular fluid.
0.12-0.14 L/kg (8-14 L in adults); indicates limited extravascular distribution (primarily extracellular fluid).
IV only; bioavailability is 100%.
IM: 100% (complete absorption); not administered orally.
Cr Cl 31-50 m L/min: 1 vial IV q8h; Cr Cl 16-30 m L/min: 1 vial IV q12h; Cr Cl 6-15 m L/min: 1 vial IV q24h; Cr Cl ≤5 m L/min: 1 vial IV q48h.
Cr Cl >55 m L/min: 1-2 g q8h; Cr Cl 35-54: 1-2 g q8h (caution); Cr Cl 11-34: 1-2 g q12h; Cr Cl <10: 1-2 g q24h (or 500 mg q12h).
No dosage adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
No dose adjustment required for hepatic impairment. Child-Pugh classification does not alter dosing.
Not approved for pediatric patients under 18 years of age.
Infants and children: 50-100 mg/kg/day IV/IM divided q8h. Severe infections: 100 mg/kg/day, max 6 g/day.
Dose based on renal function, as per adult renal adjustment; no specific age-related adjustments.
Dose based on renal function. Use lower end of dosing range due to age-related creatinine clearance decline. Monitor renal function.
No black box warning for AVYCAZ.
No FDA black box warning.
Hypersensitivity: Serious and occasionally fatal hypersensitivity reactions (anaphylaxis) have been reported in patients receiving beta-lactam antibiotics.,Clostridioides difficile-associated diarrhea (CDAD): Has been reported with nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis.,Direct Coombs test seroconversion: Positive direct Coombs test may develop during treatment, potentially interfering with crossmatching.,Central nervous system (CNS) adverse reactions: Including seizures, encephalopathy, and myoclonus have been reported, particularly in patients with renal impairment or higher doses.,Renal impairment: Dose adjustment required based on creatinine clearance.,Hepatotoxicity: Elevations of liver enzymes have been observed.,Nephrotoxicity: Concurrent use with nephrotoxic agents may increase risk.
Hypersensitivity reactions including anaphylaxis,Pseudomembranous colitis due to Clostridium difficile,Bleeding risk due to hypoprothrombinemia (rare),Seizures with high doses in renal impairment,Superinfection with prolonged use,Drug interactions with nephrotoxic agents (e.g., aminoglycosides)
Known hypersensitivity to ceftazidime, avibactam, or other cephalosporins,Severe hypersensitivity (e.g., anaphylaxis) to any other beta-lactam antibacterial agents
Known hypersensitivity to cefazolin or other cephalosporins,Severe allergic reaction to penicillins (cross-sensitivity)
No significant food interactions. However, alcohol should be avoided due to potential disulfiram-like reaction (nausea, vomiting, flushing, headache).
Alcohol may cause disulfiram-like reaction (flushing, headache, nausea, vomiting, tachycardia) due to interference with acetaldehyde metabolism; avoid alcohol during therapy and for 48 hours after last dose. No other significant food interactions.
AVYCAZ (ceftazidime-avibactam) is classified as FDA Pregnancy Category B. Animal reproduction studies in rats and rabbits at doses up to 1.6 times the human dose revealed no evidence of fetal harm. However, there are no adequate and well-controlled studies in pregnant women. Ceftazidime crosses the placenta. Risk cannot be ruled out; use only if clearly needed.
Cefazolin is Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Avoid use during first trimester unless clearly needed; second and third trimester use considered safe when indicated.
Ceftazidime is excreted in human milk in low concentrations; avibactam excretion is unknown. The M/P ratio for ceftazidime is approximately 0.02. Caution is advised due to potential disruption of infant gut flora. Consider benefits of breastfeeding versus risk of infant exposure.
Cefazolin is excreted into human breast milk in low concentrations (M/P ratio approximately 0.02-0.16). Considered compatible with breastfeeding; however, monitor infant for potential gastrointestinal disturbances and sensitization.
No specific dose adjustments are recommended for pregnancy. Physiological changes in pregnancy (e.g., increased volume of distribution, enhanced renal clearance) may alter pharmacokinetics, but data are insufficient to recommend routine dose modification. Monitor clinical response and consider therapeutic drug monitoring if available.
No specific dose adjustment recommended in pregnancy. Physiologic increases in plasma volume and renal clearance may theoretically reduce cefazolin concentrations, but standard dosing regimens are considered adequate for prophylaxis and treatment.
AVYCAZ (ceftazidime-avibactam) is a beta-lactam/beta-lactamase inhibitor combination active against ESBLs, KPC, and OXA-48 carbapenemases. It is not active against metallo-beta-lactamases (e.g., NDM, VIM). Dose adjustment required for creatinine clearance <50 m L/min. Monitor for hypersensitivity reactions, including anaphylaxis. Can cause positive direct Coombs test without hemolysis.
First-generation cephalosporin; administer IV/IM; adjust dose in renal impairment (Cr Cl <55 m L/min); monitor for hypersensitivity (cross-reactivity in 10% of penicillin-allergic patients); use for surgical prophylaxis (administer within 60 minutes before incision); drug of choice for MSSA infections; tissue penetration good, but CNS penetration limited unless meninges inflamed.
Take exactly as prescribed; complete full course even if feeling better.,Inform your doctor if you have kidney disease; blood tests may be needed to adjust dose.,Report any signs of allergic reaction (rash, hives, difficulty breathing, swelling).,May cause diarrhea; tell your doctor if severe or persistent.,Avoid alcohol during treatment and for 72 hours after last dose due to possible disulfiram-like reaction.
Take exactly as prescribed; complete full course even if feeling better.,Report any signs of allergic reaction (rash, itching, difficulty breathing, swelling) immediately.,Avoid alcohol during treatment and for at least 48 hours after last dose to prevent disulfiram-like reaction.,Inform healthcare provider if you have kidney disease, history of colitis, or are pregnant/breastfeeding.,Diarrhea may occur; report if severe, watery, or bloody (possible C. diff infection).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AVYCAZ vs ANCEF IN PLASTIC CONTAINER, answered by our medical review team.
AVYCAZ is a Cephalosporin Antibiotic that works by AVYCAZ is a combination of ceftazidime, a cephalosporin beta-lactam antibiotic, and avibactam, a non-beta-lactam beta-lactamase inhibitor. Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis. Avibactam protects ceftazidime from degradation by certain beta-lactamases, including Ambler class A, class C, and some class D enzymes.. ANCEF IN PLASTIC CONTAINER is a Cephalosporin Antibiotic that works by Cefazolin, a first-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking and autolytic enzyme inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AVYCAZ and ANCEF IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Cephalosporin Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AVYCAZ is: 1 vial (ceftazidime 2g and avibactam 0.5g) IV over 2 hours every 8 hours.. The standard adult dose of ANCEF IN PLASTIC CONTAINER is: 1-2 g IV/IM every 8 hours. Maximum 12 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AVYCAZ and ANCEF IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AVYCAZ is classified as Category C. AVYCAZ (ceftazidime-avibactam) is classified as FDA Pregnancy Category B. Animal reproduction studies in rats and rabbits at doses up to 1.6 times the human dose revealed no eviden. ANCEF IN PLASTIC CONTAINER is classified as Category C. Cefazolin is Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Avoid use during first trimester unless clearly. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.